Melflufen in multiple myeloma: the conclusion matters – Authors' reply

Fredrik H. Schjesvold*, Nicolaas A. Bakker, Pieter Sonneveld

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)e244-e245
JournalThe Lancet Haematology
Volume9
Issue number4
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

Funding Information:
FHS reports institutional grant support from Celgene, GlaxoSmithKline, Janssen, Oncopeptides AB, and Sanofi; payment or honoraria (personal) from Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides AB, Schain, Skylite DX, and Takeda; advisory board or safety monitoring board participation for AbbVie, Amgen, Celgene, Janssen, Novartis, and Oncopeptides AB; and stock or stock options from Nordic Nanovector, outside of the submitted work. FHS sold stock or stock options in Oncopeptides AB on Jan 4, 2022. NAB reports employment at Oncopeptides AB and stock or stock options from Oncopeptides AB, outside of the submitted work. PS reports grants or contracts from Amgen, Celgene, Janssen, SkylineDx, and Takeda, and payment or honoraria from Amgen, Celgene, Janssen, SkylineDx, and Takeda, outside of the submitted work.

Cite this